FEATURED:

Senate health committee to hold hearing on Trump drug pricing plan

Senate health committee to hold hearing on Trump drug pricing plan
© Greg Nash

President TrumpDonald John TrumpDemocrats slide in battle for Senate Trump believes Kushner relationship with Saudi crown prince a liability: report Christine Blasey Ford to be honored by Palo Alto City Council MORE's top health official will testify at a Senate hearing next month about the president’s proposal to reduce prescription drug costs.

Health and Human Services Secretary Alex Azar will testify at the June 12 Senate Health, Education, Labor and Pensions Committee hearing, the first time lawmakers will publicly examine Trump’s plan, which was unveiled earlier this month.

Committee Chairman Lamar AlexanderAndrew (Lamar) Lamar AlexanderOvernight Health Care — Presented by the Coalition for Affordable Prescription Drugs — Senate blocks Dem measure on short-term health plans | Trump signs bill banning drug price 'gag clauses' | DOJ approves Aetna-CVS merger | Juul ramps up lobbying Trump signs bills banning drug pricing 'gag clauses' Senate defeats measure to overturn Trump expansion of non-ObamaCare plans MORE (R-Tenn.) did not indicate whether the hearing will result in legislation.

According to Trump, the administration can tackle many of the proposals on its own. But some more significant changes — like how Medicare pays for drugs — could require Congress.

Democrats have attacked Trump’s proposals for not going far enough. For example, his plan does not include a call for Medicare to negotiate drug prices directly.

Separately, House Ways and Means Committee Chairman Kevin BradyKevin Patrick BradyOvernight Health Care — Presented by the Coalition for Affordable Prescription Drugs — Some ObamaCare premiums to decrease next year | Sanders hits back at Trump over 'Medicare for all' | Panel to investigate rising maternal mortality rates House committee to investigate rising maternal mortality rates How the Trump tax law passed: The final stretch MORE (R-Texas) said last week that he also intends to hold hearings on Trump’s drug pricing plan.

Most observers don’t expect Congress to take major action on a contentious issue like drug prices in an election year, but the hearings indicate there could at least be some discussion of the issue in Congress.